Follow-up study for people on HIV prevention pills
Treatments studied
Part of Digestive system, Infections clinical trials.
This study follows adults who are at high risk of getting HIV while they take HIV prevention pills (PrEP). It aims to learn how well PrEP fits real-life use in people at risk and who may need extra care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are HIV-negative on blood tests (EIA and Western blot).
- You are older than 18 years.
- You are at high risk for HIV from sex (for example, many partners, condomless anal sex, or related risk behaviors).
- You must be starting PrEP (daily or “on-demand”) using TDF/FTC.
- Your kidney function is good enough (glomerular filtration rate is 60 or higher).
- You cannot have an allergy to TDF and/or FTC.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a daily HIV prevention pill (F/TAF) works for people who use drugs. It also includes interviews with healthcare providers and peer navigators to understand how to better support patients.
This study is for people who are HIV-negative and want to take PrEP (a daily pill that prevents HIV). It will help researchers learn more about how to best support people taking PrEP in real-world settings.
This trial tests a new way to take HIV prevention medicine (PrEP) only around the time you have sex, using a pill called TAF/FTC. It aims to see if this 'on-demand' method is effective, safe, and acceptable, and could offer a more flexible option than taking a pill every day.
This study tests how taking two tablets of a PrEP medication (F/TAF) at once affects healthy volunteers. It helps us understand the safety and how the body processes the drug.
This study tests an all-in-one HIV prevention package for young men at higher risk of HIV. It combines a new long-acting PrEP (injectable HIV prevention) with mobile health support and sexually transmitted infection prevention. The goal is to see if this comprehensive approach works better than standard care.
This trial is for people who got exposed to HIV despite taking the long-acting PrEP shot (cabotegravir). It tests different pill-based HIV treatment plans to find the best option for them.
Hear when a new HIV Infection Primary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.